XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
M

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burden With Ropeginterferon Alfa-2b vs. SoC? Is 2L Ruxolitinib the Best Choice for HU-Resistant Patients?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
16 views
January 18, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip
MDS and MPN
21:56

Leukemic Transformations of MPNs: What Mutations Are Associated With…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

T. Mughal

257 views
25:23

MDS Essentials: How Common Are Comorbidities? Should Risk Score Dete…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Çetiner

78 views
09:57

LR-MDS: Are ESAs Effective in the Treatment of Anemia? Is PLT Transf…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Mittelman

27 views
10:25

HR-MDS: Are HMAs the Best Option? Should We Consider Changing the Pa…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Mittelman

121 views
22:45

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burd…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Ellis

16 views
12:47

MDS Updates: Can We Achieve Long-Term Transfusion Independence With …

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Garcia-Manero

310 views